BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+12.57%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$750M
AUM Growth
+$262M
(+54%)
Cap. Flow
+$209M
Cap. Flow
% of AUM
27.81%
Top 10 Holdings %
Top 10 Hldgs %
28.71%
Holding
137
New
15
Increased
36
Reduced
40
Closed
5
Top Buys
| 1 |
Align Technology
ALGN
|
$15.6M |
| 2 |
Elevance Health
ELV
|
$14.9M |
| 3 |
WBA
Walgreens Boots Alliance
WBA
|
$13.3M |
| 4 |
Amgen
AMGN
|
$11.8M |
| 5 |
Centene
CNC
|
$10.1M |
Top Sells
| 1 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
$4.67M |
| 2 |
Stryker
SYK
|
$4.32M |
| 3 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
$2.11M |
| 4 |
Becton Dickinson
BDX
|
$1.83M |
| 5 |
Zimmer Biomet
ZBH
|
$1.83M |
Sector Composition
| 1 | Healthcare | 92.09% |
| 2 | Financials | 0.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Cigna
CI
$80.6B
| $4.83M | 0.64% |
33,000
-4,722
| -13% | -$692K |
|
|
CERN
52
DELISTED
Cerner Corp
CERN
| $4.38M | 0.58% |
74,500
-24,000
| -24% | -$1.41M |
|
53
Nektar Therapeutics
NKTR
$640M
| $4.04M | 0.54% |
11,467
-933
| -8% | -$328K |
|
|
GNMK
54
DELISTED
GenMark Diagnostics, Inc
GNMK
| $4.01M | 0.53% |
+312,666
| New | +$4.01M |
|
55
Cooper Companies
COO
$13.2B
| $4M | 0.53% |
80,000
| – | – |
|
56
Johnson & Johnson
JNJ
$429B
| $3.92M | 0.52% |
31,500
-6,500
| -17% | -$810K |
|
57
Humana
HUM
$37.2B
| $3.92M | 0.52% |
19,000
+3,500
| +23% | +$722K |
|
58
Coherus Oncology, Inc. Common Stock
CHRS
$155M
| $3.7M | 0.49% |
175,000
| – | – |
|
59
McKesson
MCK
$86.5B
| $3.56M | 0.47% |
24,000
| – | – |
|
60
iShares Biotechnology ETF
IBB
$5.67B
| $3.52M | 0.47% |
36,000
+24,000
| +200% | +$2.35M |
|
61
Halozyme
HALO
$8.73B
| $3.5M | 0.47% |
270,000
-48,000
| -15% | -$622K |
|
|
ESRX
62
DELISTED
Express Scripts Holding Company
ESRX
| $3.26M | 0.43% |
49,500
| – | – |
|
63
LivaNova
LIVN
$3.13B
| $3.15M | 0.42% |
+64,189
| New | +$3.15M |
|
64
DexCom
DXCM
$31.3B
| $3.06M | 0.41% |
144,400
-19,600
| -12% | -$415K |
|
65
Neurocrine Biosciences
NBIX
$13.7B
| $2.94M | 0.39% |
68,000
-7,000
| -9% | -$303K |
|
66
Ultragenyx Pharmaceutical
RARE
$3.01B
| $2.85M | 0.38% |
42,000
-1,000
| -2% | -$67.8K |
|
67
Dentsply Sirona
XRAY
$2.78B
| $2.81M | 0.37% |
+45,000
| New | +$2.81M |
|
|
BLUE
68
DELISTED
bluebird bio
BLUE
| $2.64M | 0.35% |
2,239
| – | – |
|
69
Agios Pharmaceuticals
AGIO
$2.07B
| $2.63M | 0.35% |
45,000
| – | – |
|
70
CVS Health
CVS
$93B
| $2.62M | 0.35% |
33,400
+23,700
| +244% | +$1.86M |
|
|
TSRO
71
DELISTED
TESARO, Inc.
TSRO
| $2.46M | 0.33% |
+16,000
| New | +$2.46M |
|
|
SGEN
72
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.45M | 0.33% |
39,000
-4,000
| -9% | -$251K |
|
|
NUVA
73
DELISTED
NuVasive, Inc.
NUVA
| $2.34M | 0.31% |
31,304
-3,696
| -11% | -$276K |
|
74
Alkermes
ALKS
$4.79B
| $2.31M | 0.31% |
39,500
-3,000
| -7% | -$176K |
|
|
QGENF
75
DELISTED
QIAGEN NV
QGENF
| $2.3M | 0.31% |
79,444
-12,056
| -13% | -$349K |
|